Evolus, Inc. (EOLS) reporting calendar
Evolus, Inc. files periodic reports with the SEC as EOLS on Nasdaq. Atlas tracks 34 filed reports for this issuer, each linked to its original EDGAR accession.
- Next window
- 20 Jul 2026 – 21 Aug 2026
- Latest report
- 10-Q
- Period ended
- 31 Mar 2026
- Filed
- 4 May 2026
- Reports on record
- 34
How this window is derived. Derived from this issuer's own filing history: 9 periods at a median 91-day cadence, filed a median 36 days after period end. The SEC does not publish forward reporting dates and Atlas does not estimate one.
Open EOLS market profile
Latest filing on SEC EDGAR ↗
Pharmaceutical Preparations reporting datesAll Nasdaq reporting dates
Filed periodic reports
| Form | Period ended | Filed | Lag | SEC accession |
|---|---|---|---|---|
| 10-Q | 31 Mar 2026 | 4 May 2026 | 34 days | 0001570562-26-000066 |
| 10-K | 31 Dec 2025 | 3 Mar 2026 | 62 days | 0001628280-26-014001 |
| 10-Q | 30 Sep 2025 | 5 Nov 2025 | 36 days | 0001628280-25-049673 |
| 10-Q | 30 Jun 2025 | 5 Aug 2025 | 36 days | 0001570562-25-000098 |
| 10-Q | 31 Mar 2025 | 7 May 2025 | 37 days | 0001570562-25-000075 |
| 10-K | 31 Dec 2024 | 4 Mar 2025 | 63 days | 0001570562-25-000020 |
| 10-Q | 30 Sep 2024 | 6 Nov 2024 | 37 days | 0001570562-24-000128 |
| 10-Q | 30 Jun 2024 | 31 Jul 2024 | 31 days | 0001570562-24-000116 |
| 10-Q | 31 Mar 2024 | 7 May 2024 | 37 days | 0001570562-24-000080 |
| 10-K | 31 Dec 2023 | 7 Mar 2024 | 67 days | 0001570562-24-000041 |
| 10-Q | 30 Sep 2023 | 7 Nov 2023 | 38 days | 0001570562-23-000115 |
| 10-Q | 30 Jun 2023 | 2 Aug 2023 | 33 days | 0001570562-23-000088 |
| 10-Q | 31 Mar 2023 | 9 May 2023 | 39 days | 0001570562-23-000070 |
| 10-K | 31 Dec 2022 | 8 Mar 2023 | 67 days | 0001570562-23-000038 |
| 10-Q | 30 Sep 2022 | 8 Nov 2022 | 39 days | 0001570562-22-000143 |
| 10-Q | 30 Jun 2022 | 2 Aug 2022 | 33 days | 0001570562-22-000119 |
| 10-Q | 31 Mar 2022 | 10 May 2022 | 40 days | 0001570562-22-000102 |
| 10-K | 31 Dec 2021 | 3 Mar 2022 | 62 days | 0001570562-22-000067 |
| 10-Q | 30 Sep 2021 | 2 Nov 2021 | 33 days | 0001570562-21-000173 |
| 10-Q | 30 Jun 2021 | 4 Aug 2021 | 35 days | 0001570562-21-000148 |
| 10-Q | 31 Mar 2021 | 12 May 2021 | 42 days | 0001570562-21-000141 |
| 10-K | 31 Dec 2020 | 25 Mar 2021 | 84 days | 0001570562-21-000093 |
| 10-Q | 30 Sep 2020 | 29 Oct 2020 | 29 days | 0001570562-20-000122 |
| 10-Q | 30 Jun 2020 | 10 Aug 2020 | 41 days | 0001570562-20-000111 |
| 10-Q | 31 Mar 2020 | 11 May 2020 | 41 days | 0001570562-20-000087 |
| 10-K | 31 Dec 2019 | 25 Feb 2020 | 56 days | 0001570562-20-000061 |
| 10-Q | 30 Sep 2019 | 4 Nov 2019 | 35 days | 0001570562-19-000143 |
| 10-Q | 30 Jun 2019 | 12 Aug 2019 | 43 days | 0001570562-19-000131 |
| 10-Q | 31 Mar 2019 | 1 May 2019 | 31 days | 0001570562-19-000070 |
| 10-K | 31 Dec 2018 | 20 Mar 2019 | 79 days | 0001570562-19-000038 |
| 10-Q | 30 Sep 2018 | 5 Nov 2018 | 36 days | 0001570562-18-000118 |
| 10-Q | 30 Jun 2018 | 2 Aug 2018 | 33 days | 0001570562-18-000100 |
| 10-Q | 31 Mar 2018 | 10 May 2018 | 40 days | 0001570562-18-000037 |
| 10-K | 31 Dec 2017 | 29 Mar 2018 | 88 days | 0001570562-18-000013 |
Source: SEC EDGAR company submissions for CIK 0001570562. Atlas publishes filed facts only. The SEC does not publish forward reporting dates, so no announced future date is claimed here.